Todd Lopeman is a senior biotechnology and vaccines executive with more than 30 years of industry experience, including more than 12 years in executive leadership roles.
Prior to Vaxart, Mr. Lopeman served as Senior Vice President at Dynavax Technologies, a Sanofi Company. He played a key leadership role in advancing technical operations through the approval and commercialization of HEPLISAV-B®, Dynavax’s first U.S. FDA-approved product, and the CpG 1018 adjuvant platform, which supported multiple authorized COVID-19 vaccine programs globally. Before that, Mr. Lopeman held technical and leadership roles at Novartis, Sandoz, Bristol Myers Squibb, and GSK.
Mr. Lopeman earned a B.S. in Chemical Engineering from North Carolina State University.
